Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M PEROU

Showing results (321-330 of 476) with videos related to

Pageof 48
Sort By:
Cancer Research|April 16, 2009
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerRobert J Crowder, Chanpheng Phommaly, Yu Tao, et al.
ESMO Open|April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysisF Schettini, O Martínez-Sáez, C Falato, et al.
BMC Medical Genomics|November 3, 2011
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low featuresVilde D Haakensen, Ole Christian Lingjaerde, Torben Lüders, et al.
BMC Bioinformatics|January 30, 2020
Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approachesArran K Turnbull, Cigdem Selli, Carlos Martinez-Perez, et al.
Breast Cancer Research and Treatment|February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyMiguel Martin, Jan C Brase, Amparo Ruiz, et al.
Bioengineering & Translational Medicine|November 18, 2024
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancerNatasha Vinod, Duhyeong Hwang, Sloane Christian Fussell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)William M Sikov, Donald A Berry, Charles M Perou, et al.
Nature Communications|January 24, 2013
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11Jessica Bockhorn, Rachel Dalton, Chika Nwachukwu, et al.
Biorxiv : the Preprint Server for Biology|March 16, 2026
Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancersMatthew D Sutcliffe, Kevin R Mott, Tulay Yilmaz-Swenson, et al.
ESMO Open|March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)G Villacampa, T Pascual, F Brasó-Maristany, et al.
Pageof 48

Showing results (321-330 of 476) with videos related to

Sort By:
Pageof 48
Cancer Research|April 16, 2009
PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancerRobert J Crowder, Chanpheng Phommaly, Yu Tao, et al.
ESMO Open|April 19, 2023
Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysisF Schettini, O Martínez-Sáez, C Falato, et al.
BMC Medical Genomics|November 3, 2011
Gene expression profiles of breast biopsies from healthy women identify a group with claudin-low featuresVilde D Haakensen, Ole Christian Lingjaerde, Torben Lüders, et al.
BMC Bioinformatics|January 30, 2020
Unlocking the transcriptomic potential of formalin-fixed paraffin embedded clinical tissues: comparison of gene expression profiling approachesArran K Turnbull, Cigdem Selli, Carlos Martinez-Perez, et al.
Breast Cancer Research and Treatment|February 25, 2016
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyMiguel Martin, Jan C Brase, Amparo Ruiz, et al.
Bioengineering & Translational Medicine|November 18, 2024
Combination of polymeric micelle formulation of TGFβ receptor inhibitors and paclitaxel produces consistent response across different mouse models of Triple-negative breast cancerNatasha Vinod, Duhyeong Hwang, Sloane Christian Fussell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 6, 2014
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)William M Sikov, Donald A Berry, Charles M Perou, et al.
Nature Communications|January 24, 2013
MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11Jessica Bockhorn, Rachel Dalton, Chika Nwachukwu, et al.
Biorxiv : the Preprint Server for Biology|March 16, 2026
Transcriptomic profiling of mouse mammary tumors enables prognostic and predictive biomarker discovery for human breast cancersMatthew D Sutcliffe, Kevin R Mott, Tulay Yilmaz-Swenson, et al.
ESMO Open|March 5, 2024
Prognostic value of HER2DX in early-stage HER2-positive breast cancer: a comprehensive analysis of 757 patients in the Sweden Cancerome Analysis Network-Breast dataset (SCAN-B)G Villacampa, T Pascual, F Brasó-Maristany, et al.
Pageof 48